Mission Statement, Vision, & Core Values (2026) of Syngene International Limited.

Founded in 1993, Syngene International Limited has grown into an integrated research, development and manufacturing organization that partners with pharma, biotech, nutrition, animal health, consumer goods and specialty chemical companies, operating with a workforce of over 8,200 employees - including more than 5,600 scientists - across multiple facilities and a recently acquired biologics manufacturing site in Baltimore, Maryland, USA, all driven by a mission to improve the lives of people, animals and patients through client partnerships while minimizing environmental impact, a vision to be a world-class partner delivering innovative scientific solutions, and core values of integrity, excellence and professionalism that guide its governance, sustainability efforts and commitment to shared value for clients, communities, employees and shareholders

Syngene International Limited (SYNGENE.NS) - Intro

• Founded: 1993
• Headquarters: Bangalore, India (multiple campus facilities)
• Global reach: India-based operations with a biologics manufacturing facility in Baltimore, Maryland, USA
• Workforce: >8,200 employees, including >5,600 scientists

• Mission: To accelerate scientific discovery and deliver high-quality, compliant R&D and manufacturing services that create shared value for clients, employees, communities, and shareholders.
• Vision: To be a world-class, trusted partner enabling innovation across the life sciences value chain through scientific excellence, scalable manufacturing, and sustainable practices.
• Value creation model: Client-focused partnerships, long-term integrated collaborations, operational excellence, regulatory compliance and continuous reinvestment in capabilities to deliver predictable outcomes and shared stakeholder value.

• Professionalism - scientific rigor, operational discipline and client-centricity
• Integrity - ethical conduct, transparency and regulatory compliance
• Excellence - continuous improvement, quality and innovation
• Accountability - governance frameworks, risk management and stakeholder reporting

• Environmental focus: energy efficiency, waste minimization and initiatives to reduce carbon footprint across campuses and manufacturing sites.
• Workplace safety: robust EHS systems aligned with national and international standards; continuous training and incident-reduction targets.
• Community engagement: health, education and local economic development programs in communities around major facilities.

• Expand integrated discovery-to-commercialization partnerships with global pharma and biotech clients
• Scale biologics manufacturing and cell & gene therapy support capabilities (including US facility)
• Increase value-added services (CDMO, bespoke discovery platforms) and deepen long-term client collaborations
• Embed sustainability and digitalization across processes to enhance efficiency and transparency

Syngene International Limited (SYNGENE.NS) - Overview

• Client partnerships: long-term collaborations with global pharma, biotech, agrochemical, and consumer health companies to co-develop and deliver solutions across the drug discovery and development lifecycle.
• Health impact: focused on human and animal health through discovery biology, chemistry, biologics, GMP manufacturing and clinical supply capabilities.
• Environmental stewardship: commitment to reducing emissions, waste and water usage and embedding sustainable practices across campuses and supply chains.
• Social responsibility: workforce development, community engagement, and ethical governance as core pillars of operations.

• Global client base exceeding 400+ companies across North America, Europe and Asia, enabling cross-border R&D partnerships.
• Integrated campus footprint of approximately 2.5-3.0 million sq. ft. of laboratory and manufacturing facilities supporting discovery to commercial supply.
• Workforce of ~5,000-5,700 employees spanning life-science research, development, manufacturing and quality functions.
• Project scale: thousands of discovery programs and hundreds of development and clinical-supply engagements delivered since inception.

• Quality & compliance: multi-site GMP accreditation enabling clinical and commercial biologics and small-molecule manufacturing to global standards.
• Sustainability targets: programs to reduce greenhouse gas intensity, optimize water use and improve waste management across the organization.
• Partnership model: revenue mix that balances discovery services, development & manufacturing, and integrated research alliances-fostering mutually beneficial long-term client relationships.
• Investment focus: continued capital deployment in capacity expansion, platform technologies (e.g., biologics, cell line development, high-throughput discovery) and digital tools to enhance scientific outcomes.

Syngene International Limited (SYNGENE.NS) - Mission Statement

• Deliver end‑to‑end R&D and integrated services spanning discovery biology, medicinal chemistry, ADME/PK, biologics, clinical trial support and commercial manufacturing.
• Commit to scientific excellence and regulatory compliance to enable predictable, scalable outcomes for partners.
• Invest in cutting‑edge infrastructure, automation and digital platforms to improve speed, reproducibility and cost‑effectiveness.
• Foster collaborative partnerships that transfer know‑how, share risk and align incentives with global biotech and pharma clients.

• Position as a world‑class partner by expanding capabilities-biologics, complex small‑molecule chemistry, cell and gene therapy enablement and GMP manufacturing.
• Grow global footprint through customer‑aligned facilities and joint development alliances with multinational and emerging biotech firms.
• Drive innovation via internal technology platforms, automation and data‑driven workflows to shorten timelines from discovery to IND/CTA.

• Facility expansion and capacity utilisation: targeted investments to add biologics and GMP drug‑product capabilities to capture higher‑value engagements.
• Client diversification: increase share of business from large pharma and biotech partnerships, moving from fee‑for‑service models to risk‑sharing and longer‑term alliances.
• Technology platforms: scaling automation, high‑throughput screening and AI‑enabled data analytics to reduce cycle times and improve predictability.
• Quality & compliance: continuous upgrades to meet global regulatory standards (US FDA, EMA) for contract manufacturing and clinical supply services.

• Acquisition of or investment in new facilities to broaden service offerings and geographic coverage.
• Long‑term strategic partnerships to co‑develop molecules and share downstream manufacturing.
• Recruitment and retention programs to grow scientific talent pool, increasing R&D bench strength and specialist capabilities.

Syngene International Limited (SYNGENE.NS): Vision Statement

• Integrity: Ethical conduct and regulatory compliance underpin decision-making across labs, clinical support, and commercialization services.
• Excellence: A commitment to scientific rigor, quality management systems (GLP/GMP/GCP), and superior client delivery, reflected in high customer-satisfaction metrics.
• Professionalism: Skilled teams, transparent governance, and client-centric project management create sustained trust and long-term partnerships.

• Integrated service model: discovery, development, clinical research, and manufacturing support under one global delivery framework.
• Quality and compliance: continuous investments in quality systems and accreditations to meet global regulatory expectations.
• Talent and culture: structured learning programs, cross-functional teams, and ethical codes to embed core values into daily operations.

• Integrity - demonstrated through adherence to global regulatory audits, zero-tolerance policies for data manipulation, and sustained client compliance records.
• Excellence - measured by delivery timelines (on-time project delivery >90% for priority programs) and high technical success rates in discovery assays.
• Professionalism - shown by low client churn, multi-year strategic agreements with top-tier global pharma, and transparent governance practices.

• Capacity expansion: capital investments to support biologics and advanced modality programs, increasing throughput and reducing time-to-clinic.
• Digital and data: deploying informatics, AI-enabled assay analytics, and electronic lab management to raise reproducibility and accelerate decision-making.
• Sustainability & governance: ESG targets incorporated into operations, focusing on energy efficiency, waste management, and ethical sourcing.